The take-home message from these studies is that we have treatment that is effective and that the risk from depression is far greater than the risk of treatment.

Medicare Part D is the single most significant mental health policy initiative to have been undertaken in the last decade. We think it would be extremely helpful to have a sense of how this is actually impacting our patients and practitioners. The only way of systematically assessing the strengths and weaknesses of the new program is a survey that would get a representative sample of the experiences our patients are having.

What the FDA initiated was in some ways a natural experiment. This is the kind of rigorous scientific information the FDA should consider in evaluating its decisions.

One thing we do for treatment is to assess those risk factors and minimize them.

What's changed over the last few years is the risk of the treatment has gone down, down, down and down, so that now we're comfortable fixing almost every heart defect pretty much right after birth.

Every secret place of detention is usually a higher risk for ill treatment, that the danger of secrecy.